COLLABORATION AND OTHER AGREEMENTS (Tables)

9 Months Ended

Mar. 31, 2019

Collaboration and Other Agreements [Abstract]

Schedule of total revenue

The following table summarizes total revenue recognized for the periods indicated (in thousands):

	Three Months Ended				Nine Months Ended
	March 31,				March 31,
	2019		2018		2019		2018
Product royalties
Pierre Fabre	$	835	$	—	$	1,159	$	—
Ono	102		—		102		—
Total product royalties	$	937	$	—	$	1,261	$	—
Collaboration and other revenue
Pierre Fabre	$	10,704	$	5,347	$	22,160	$	12,370
Mirati	1,500		1,376		3,710		4,187
Loxo	—		2,416		2,403		7,069
Other partners	561		974		3,050		3,003
Total collaboration and other revenue	12,765		10,113		31,323		26,629
License and milestone revenue
Loxo	—		—		44,000		1,107
Pierre Fabre	750		750		17,250		2,250
Ono	4,596		4,665		6,433		6,502
ASLAN	—		23,000		—		23,000
Asahi Kasei	—		—		—		10,000
Other partners	1,382		3,088		2,115		3,505
Total license and milestone revenue	6,728		31,503		69,798		46,364
Total collaboration and license revenue	$	19,493	$	41,616	$	101,121	$	72,993
Reimbursement revenue
Novartis	$	9,169	$	24,751	$	29,970	$	65,338

Schedule of deferred revenue

Deferred revenue balances were as follows for the dates indicated (in thousands):

	March 31,			June 30,
	2019			2018
Ono	$	24,799		$	27,555
Pierre Fabre (1)	26,098			22,394
Mirati	1,042			2,468
Loxo	—			2,403
Other	—			2,000
Total deferred revenue	51,939			56,820
Less: Current portion	(13,627		)	(12,350		)
Deferred revenue, non-current portion	$	38,312		$	44,470

(1) Balance as of March 31, 2019 includes a $6.0 million prepayment for commercial drug supply of